

POXEL S.A.

ISIN: FR0012432516 WKN: - Asset Class: **Stock**

Company



2022/12/09 17:35:23

Price
1.12 EUR

Difference ▲ 0.00%(0.00)



Contact Details

POXEL SA
- -
259/261, Avenue Jean Jaurès
69007 Lyon

Tel: 33-4-37-37-20-12
Fax: 33-4-37-70-88-15
Web: <http://www.poxel.com>
E-mail: -

Company Profile

Poxel SA operates as a clinical-stage biopharmaceutical company. The firm focuses on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as non-alcoholic steatohepatitis (NASH). Its drug candidates include Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	36,337,000		45,964,000		52,888,000	
Common stock capital		574,000		570,000		521,000
Fixed assets	18,477,000		19,000,000		19,058,000	
Equity capital of a company		8,131,000		26,766,000		38,786,000
Cash and cash equivalents	28,754,000		15,587,000		18,161,000	
Accrued liabilities		688,000		753,000		469,000
Other assets	-		-		-	
Current liabilities		15,901,000		16,459,000		30,849,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		30,782,000		21,739,000		2,311,000
Different income		-		-		-
Other liabilities		0		0		0
Total assets	54,814,000	54,814,000	64,964,000	64,964,000	71,946,000	71,946,000

Balance notes

	2021	2020	2019
Accounting standard	IFRS	IFRS	IFRS
Employees	56	53	-
Equity ratio	14.83%	41.20%	53.91%
Debt-equity ratio	574.14%	142.71%	85.49%

Others

	2021	2020	2019
Tax Expense Rate	8.71%	7.23%	14.52%

POXEL S.A.

ISIN: FR0012432516 WKN: - Asset Class: **Stock**

Income statement

	2021	2020	2019
Turnover	13,397,000	6,806,000	26,557,000
Net income	-23,763,000	-31,858,000	-25,743,000
EBIT	-23,128,000	-33,056,000	-30,104,000
Operating income before taxes	-26,030,000	-34,339,000	-30,115,000
Cash Flow	-18,771,000	-26,200,000	-25,448,000
Net interest income	-2,902,000	-1,283,000	-11,000
Research and development expenses	27,479,000	29,235,000	44,550,000
Income taxes	-2,267,000	-2,481,000	-4,372,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	239,232	128,415	-

Board of Directors

Pierre Legault	Chairman of Supervisory Board
Janice Bourque	Member of Supervisory Board
Kumi Sato	Member of Supervisory Board
Pascale Boissel	Member of Supervisory Board
Richard Kender	Member of Supervisory Board

Members of Management Board